Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

Report ID: 51298 | Published Date: Sep 2024 | No. of Page: 140 | Base Year: 2023 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	28
2.4 Emerging Opportunities and Market Trends	31
2.5 Porter’s Fiver Forces Analysis	35
3 Segmentation of Europe Market by Vaccine Type	39
3.1 Market Overview by Vaccine Type	39
3.2 Live/Attenuated Vaccines	41
3.3 Inactivated Vaccines	42
3.4 Subunit Vaccines	43
3.5 Toxoid Vaccines	44
3.6 Conjugate Vaccines	45
3.7 Recombinant Vector Vaccines	46
3.8 Other Vaccines	47
4 Segmentation of Europe Market by Disease	48
4.1 Market Overview by Disease	48
4.2 Vaccines for Pneumococcal Disease	50
4.3 Vaccines for Poliovirus	51
4.4 Vaccines for Hepatitis	52
4.5 Vaccines for Influenza	53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR)	54
4.7 Vaccines for Varicella	55
4.8 Vaccines for Human Papilloma Virus	56
4.9 Vaccines for COVID-19	57
4.10 Vaccines for Other Diseases	60
5 Segmentation of Europe Market by Administration	61
5.1 Market Overview by Administration	61
5.2 Intramuscular Route	63
5.3 Subcutaneous Route	64
5.4 Oral Route	65
5.5 Intravenous Injection	66
5.6 Other Administration Routes	67
6 Segmentation of Europe Market by Patient	68
6.1 Market Overview by Patient	68
6.2 Pediatric Vaccines	70
6.3 Adult Vaccines	72
7 European Market 2020-2026 by Country	74
7.1 Overview of European Market	74
7.2 UK	77
7.3 France	80
7.4 Germany	83
7.5 Spain	86
7.6 Italy	89
7.7 Russia	92
7.8 Rest of European Market	95
8 Competitive Landscape	97
8.1 Overview of Key Vendors	97
8.2 New Product Launch, Partnership, Investment, and M&A	100
8.3 Company Profiles	101
AstraZeneca plc	101
Bavarian Nordic A/S	104
China National Biotec Group Company Ltd.	107
CSL Ltd.	109
Daiichi Sankyo Co. Ltd	111
Emergent BioSolutions Inc.	113
GlaxoSmithKline plc	115
Johnson & Johnson	119
Merck & Co.	121
Moderna Inc.	123
Novavax, Inc.	124
Pfizer Inc.	126
Sanofi SA	130
Takeda Pharmaceutical Co. Ltd.	132
9 Investing in Europe Market: Risk Assessment and Management	134
9.1 Risk Evaluation of Europe Market	134
9.2 Critical Success Factors (CSFs)	137
Related Reports and Products	140
Table 1.  Snapshot of Europe Preventive Vaccines Market in Balanced Perspective, 2020-2026	17
Table 2. Growth Rate of World GDP, 2020-2022	22
Table 3.  Main Product Trends and Market Opportunities in Europe Preventive Vaccines Market	31
Table 4. Europe Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	39
Table 5. Europe Preventive Vaccines Market by Disease, 2016-2026, $ mn	48
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021	58
Table 7. Europe Preventive Vaccines Market by Administration, 2016-2026, $ mn	61
Table 8. Europe Preventive Vaccines Market by Patient, 2016-2026, $ mn	68
Table 9. Europe Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn	71
Table 10. Europe Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn	73
Table 11. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn	76
Table 12. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	78
Table 13. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn	78
Table 14. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn	79
Table 15. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	81
Table 16. France Preventive Vaccines Market by Disease, 2016-2026, $ mn	81
Table 17. France Preventive Vaccines Market by Administration, 2016-2026, $ mn	82
Table 18. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	84
Table 19. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn	84
Table 20. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn	85
Table 21. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	87
Table 22. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn	87
Table 23. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn	88
Table 24. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	90
Table 25. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn	90
Table 26. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn	91
Table 27. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	93
Table 28. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn	93
Table 29. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn	94
Table 30. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn	96
Table 31. AstraZeneca plc: Company Snapshot	101
Table 32. AstraZeneca plc: Revenue, 2018-2020, $ bn	102
Table 33. Bavarian Nordic A/S: Company Snapshot	104
Table 34. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020	105
Table 35. China National Biotec Group Company Ltd.: Company Snapshot	107
Table 36. CSL Ltd.: Company Snapshot	109
Table 37. Daiichi Sankyo Co. Ltd.: Company Snapshot	111
Table 38. Emergent BioSolutions Inc.: Company Snapshot	113
Table 39. GlaxoSmithKline: Company Snapshot	115
Table 40. GlaxoSmithKline: Business Segmentation	116
Table 41. GlaxoSmithKline: Product Portfolio	117
Table 42. GlaxoSmithKline: Revenue, 2018-2020, $ bn	118
Table 43. GlaxoSmithKline: Recent Developments	118
Table 44. Johnson & Johnson: Company Snapshot	119
Table 45. Johnson & Johnson: Business Segments	120
Table 46. Merck & Co., Inc.: Company Snapshot	121
Table 47. Merck & Co., Inc.: Business Segmentation	121
Table 48. Merck & Co., Inc.: Revenue, 2018-2020, $ bn	122
Table 49. Moderna Inc.: Company Snapshot	123
Table 50. Novavax, Inc.: Company Snapshot	124
Table 51. Pfizer Inc.: Company Snapshot	126
Table 52. Pfizer Inc.: Business Segmentation	127
Table 53. Pfizer Inc.: Product Portfolio	128
Table 54. Pfizer Inc.: Revenue, 2018-2020, $ bn	129
Table 55. Pfizer Inc.: Recent Developments	129
Table 56. Sanofi: Company Snapshot	130
Table 57. Sanofi: Business Segmentation	130
Table 58. Sanofi: Revenue, 2018-2020, $ bn	131
Table 59. Takeda Pharmaceutical Co. Ltd.: Company Snapshot	132
Table 60.  Risk Evaluation for Investing in Europe Market, 2020-2026	135
Table 61. Critical Success Factors and Key Takeaways	138
Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026	16
Figure 4. Europe Preventive Vaccines Market, 2016-2026, $ mn	19
Figure 5. Development Stages of Preventive Vaccines	20
Figure 6. Impact of COVID-19 on Business	23
Figure 7. Primary Drivers and Impact Factors of Europe Preventive Vaccines Market	25
Figure 8. Primary Restraints and Impact Factors of Europe Preventive Vaccines Market	28
Figure 9. Investment Opportunity Analysis	32
Figure 10. Porter’s Fiver Forces Analysis of Europe Preventive Vaccines Market	35
Figure 11. Breakdown of Europe Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue	40
Figure 12. Contribution to Europe 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%)	40
Figure 13. Europe Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn	41
Figure 14. Europe Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn	42
Figure 15. Europe Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn	43
Figure 16. Europe Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn	44
Figure 17. Europe Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn	45
Figure 18. Europe Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn	46
Figure 19. Europe Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn	47
Figure 20. Breakdown of Europe Preventive Vaccines Market by Disease, 2020-2026, % of Revenue	49
Figure 21. Contribution to Europe 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%)	49
Figure 22. Europe Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn	50
Figure 23. Europe Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn	51
Figure 24. Europe Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn	52
Figure 25. Europe Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn	53
Figure 26. Europe Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn	54
Figure 27. Europe Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn	55
Figure 28. Europe Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn	56
Figure 29. Europe Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn	57
Figure 30. Europe Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn	60
Figure 31. Breakdown of Europe Preventive Vaccines Market by Administration, 2020-2026, % of Revenue	62
Figure 32. Contribution to Europe 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%)	62
Figure 33. Europe Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn	63
Figure 34. Europe Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn	64
Figure 35. Europe Preventive Vaccines Market: Oral Route, 2016-2026, $ mn	65
Figure 36. Europe Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn	66
Figure 37. Europe Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn	67
Figure 38. Breakdown of Europe Preventive Vaccines Market by Patient, 2020-2026, % of Revenue	68
Figure 39. Contribution to Europe 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%)	69
Figure 40. Europe Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn	70
Figure 41. Europe Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn	72
Figure 42. Breakdown of European Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue	75
Figure 43. Contribution to Europe 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)	76
Figure 44.  Preventive Vaccines Market in UK, 2016-2026, $ mn	77
Figure 45.  Preventive Vaccines Market in France, 2016-2026, $ mn	80
Figure 46.  Preventive Vaccines Market in Germany, 2016-2026, $ mn	83
Figure 47.  Preventive Vaccines Market in Spain, 2016-2026, $ mn	86
Figure 48.  Preventive Vaccines Market in Italy, 2016-2026, $ mn	89
Figure 49.  Preventive Vaccines Market in Russia, 2016-2026, $ mn	92
Figure 50.  Preventive Vaccines Market in Rest of Europe, 2016-2026, $ mn	95
Figure 51. Growth Stage of Europe Preventive Vaccines Industry over the Forecast Period	97
Figure 52.  Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars)	102
Companies Included in Reports:
Key Players (this may not be a complete list and extra companies can be added upon request): 
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.	
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Frequently Asked Questions
Europe Preventive Vaccines Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Europe Preventive Vaccines Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Europe Preventive Vaccines Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports